Dermata Therapeutics, Inc.
DRMA · XNASCIK 1853816fmd_0YP44KSQVD7XW7DA20QY7XMC1MManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | – | (0) | 0 | – | – | – |
| Research and development | 2 | 3 | 6 | 4 | 8 | 3 |
| Selling, general and administrative | – | – | – | – | 4 | 5 |
| Total operating expenses | – | – | 10 | 8 | 13 | 8 |
| Operating income | (3) | (8) | (10) | (8) | (13) | (8) |
| Interest expense | 0 | 0 | – | – | – | – |
| Interest and investment income | – | – | – | – | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | – |
| Net income | (3) | (8) | (10) | (8) | (12) | (8) |
| Net income to common shareholders | (3) | (10) | (10) | – | – | – |